Ribociclib Also Demonstrated Efficacy in Premenopausal Metastatic Hormone-Positive Breast Cancer

Breast cancer is the most common cancer in women. Patients diagnosed under age 50 account for approximately 40%. Of these patients, 2/3 are hormone receptor -positive and HER2 receptor-negative. Among them, in the metastatic (stage 4) patient group, hormone-suppressing treatment together with ovarian suppression is one of the most important first-line options. However, because resistance to these drugs develops, these treatments alone cannot provide the desired response. Breast cancer hormonal therapies encounter resistance involving the cell proliferation control proteins CDK 4/6, whose excessive activity causes excessive cancer cell proliferation.
Although drugs known as CDK4/6 inhibitors have demonstrated effectiveness in postmenopausal patients, their premenopausal effectiveness was unknown. Ribociclib (Kisqali), one of the CDK4/6 inhibitors, was shown to be effective together with the hormone-suppressing treatment letrozole in patients who had not entered menopause.
One of oncology’s respected journals, The Lancet Oncology, published the MONALEESA-7 study, enrolling patients from 30 countries and 188 centers: 672 premenopausal patients with metastatic hormone receptor-positive, HER2-negative disease. All patients received a monthly 3.6 mg vial of goserelin for ovarian suppression. Hormone-suppressing treatment consisted of tamoxifen or letrozole; some patients also received ribociclib and others placebo (a drug containing no active ingredient).
The study showed that ribociclib prolonged the time until disease worsening (progression-free survival) by an additional 11 months (24 months versus 13 months). The most common side effect was a reduction in blood neutrophil count (neutropenia) . Serious side effects were more frequent in ribociclib recipients, at 6%, but no patient deaths due to these side effects were observed.
In light of this study, we can say that CDK4/6 inhibitors can also be used safely in premenopausal patients. A key question is how the effectiveness of these drugs compares with chemotherapy in premenopausal patients. These studies are ongoing. We will continue informing you as their results are announced.
Sources
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
The Lancet Oncology Published: May 24, 2018
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.